A Snapshot of Attending Companies:

7th Targeted Protein Degradation & Induced Proximity Summit

Propelling PROTACs, Glues, & Novel TACs Drugs Towards the First Approval

With a flurry of high capital collaborations and partnership deals from the likes of C4T, Merck KgGA, Monte Rosa, Proxygen, Orum, and momentum building in clinic with BTK degraders, ER degraders and many more assets. It has never been more important to re-join forces at the 7th TPD & Induced Proximity Summit, the longest standing and most comprehensive protein degradation and proximity based conference.

Spanning foundational research and discovery, through to IND-filing and clinical trials, this is the world’s definitive meeting to discuss opportunities and challenges the TPD & Induced Proximity field must address to expand the target space and facilitate the discovery and development of therapeutically relevant degraders, blockers, stabilizers and inducers of protein-protein interactions. Whether you’re entering the TPD & Induced Proximity space for the first time or a well-seasoned TPD veteran, this forum will equip you with the knowhow and connections to make rapid advances in your work.

Assembling over 450 TPD & Induced Proximity enthusiasts from across every corner of the landscape, we have left no stone unturned in our duty to continue to deliver the full breadth and depth of protein degradation and modulation research with SureTACs, EpiTACs, RIPTACs, Molecular Gates, and so much more.

The 7th TPD & Induced Proximity Summit is the field’s singular, one-stop-shop to gain unparalleled overview of cutting-edge R&D, whilst diving deep into end-to-end development strategy to propel degraders towards the first clinical approval.

FULL EVENT GUIDE

TPD & Induced Proximity Summit

Relive the Highlights:

2024 Expert Speakers Include:

Alessio Ciulli

Founder, Director & Professor - Chemical & Structural Biology

University of Dundee

Nello Mainolfi

Founder, President & Chief Executive Officer

Kymera Therapeutics

Sharon Townson

Chief Technology Officer

Monte Rosa Therapeutics

Stuart Schreiber

Professor - Morris Loeb. Chemistry & Chemical Biology, Emeritus Howard Hughes Medical Institute Investigator

Arena Bioworks

Adrian Gottschalk

Chief Executive Officer

Foghorn Therapeutics

Andrew Hirsch

President & Chief Executive Officer

C4 Therapeutics

Arthur T. Sands

Chief Executive Officer

Nurix Therapeutics

Chinatsu Sakata-Sakur

Vice President

Astellas Pharma

Brand New Presenting Companies for This Year:

47978 - web banners

“Four days of high value content and engaging speakers and moderators - a must for those invested in the field of targeted degradation”

Associate Director

novartis
Untitled design (3)

“In such a rapidly evolving field, it is crucial to have a touchpoint to check in on progress across companies. This is an excellent forum to meet the key players in the field and absorb new advances”

Senior Director of Chemistry

“Fantastic speakers, great audience, well organized, the most important conference in the TPD field. Impossible to skip if you want to stay informed of recent developments in the field”

Senior Vice President 

Cullgen+Logo

Proud to Partner With:

Expertise Partner:

Program Partners:

Other Events in the Small Molecules & TPD World Series